Canada markets closed

Intellipharmaceutics International Inc. (IPCI.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.17000.0000 (0.00%)
At close: 03:57PM EST
Full screen
Previous Close0.1700
Open0.1600
Bid0.1600 x 0
Ask0.1800 x 0
Day's Range0.1600 - 0.1800
52 Week Range0.1100 - 0.6000
Volume25,910
Avg. Volume62,543
Market Cap5.626M
Beta (5Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-0.2240
Earnings DateOct. 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    Intellipharmaceutics Mourns the Death of Valued Board Member Kenneth Eugene Keirstead

    TORONTO, ON / ACCESSWIRE / January 13, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today with great sadness that Kenneth Keirstead, a member of the Company's Board of Directors, has passed away.

  • ACCESSWIRE

    Intellipharmaceutics Comments on Recent Trading Activity

    TORONTO, ON / ACCESSWIRE / December 22, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, is issuing this press release in response to a request from the Investment Industry Regulatory Organization of Canada ("IIROC") to comment on the recent trading activity of i

  • ACCESSWIRE

    Intellipharmaceutics Announces Third Quarter 2021 Results

    TORONTO, ON / ACCESSWIRE / October 15, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2021.